Apellis Pharmace Stock Price, News & Analysis

Apellis Pharmaceuticals (APLS) announced the approval of equity inducement awards for a new employee, effective January 3, 2022. The award consists of options to purchase 60,000 shares at an exercise price of $48.77 and 20,000 restricted stock units (RSUs). The options will vest over four years, with 25% vesting on the first anniversary. This action is aligned with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent by providing long-term incentive compensation.

Apellis Pharmaceuticals (Nasdaq: APLS) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 a.m. ET. The presentation will include a live Q&A session and will be accessible via a webcast on the company’s website. A replay will be available for 30 days post-event, along with the presentation slides posted online at 8:00 a.m. ET on the same day. Apellis is focused on developing transformative therapies targeting the complement system for various debilitating diseases.

Apellis Pharmaceuticals announced that the European Commission has approved Aspaveli (pegcetacoplan), the first targeted C3 therapy for paroxysmal nocturnal hemoglobinuria (PNH), aimed at adults who remain anemic after C5 inhibitor treatment. This approval is based on the PEGASUS Phase 3 study showing Aspaveli's effectiveness over eculizumab in improving hemoglobin levels. Aspaveli will enjoy market exclusivity in the EU due to its orphan drug designation, supporting its potential to enhance patient care for PNH.

Apellis Pharmaceuticals (Nasdaq: APLS) and Sobi™ announced positive data for Empaveli™ (pegcetacoplan) in treating paroxysmal nocturnal hemoglobinuria (PNH) at the ASH Annual Meeting. Results from the Phase 3 PRINCE study revealed significant improvements in treatment-naïve patients: 46% achieved hemoglobin normalization without transfusions, with a mean hemoglobin rise from 9.4 g/dL to 12.8 g/dL. The treatment also resulted in rapid reductions in lactate dehydrogenase (LDH) levels. The safety profile was consistent, with lower serious adverse events compared to standard care.

Apellis Pharmaceuticals (Nasdaq: APLS) will present at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, at 8:00 a.m. ET. The presentation will be conducted in a virtual format and can be accessed via a live webcast on the company’s website. A replay of the event will be available for 90 days post-conference. Apellis is a global leader in complement therapies, focusing on innovative treatments for diseases related to the complement cascade in various fields, including hematology and neurology.

Apellis Pharmaceuticals (APLS) announced the closing of its underwritten public offering, selling a total of 10,062,500 shares at $40.00 each. This offering generated gross proceeds of approximately $402.5 million before expenses. The underwriters fully exercised their option to purchase an additional 1,312,500 shares. The offering was conducted under an effective shelf registration statement filed with the SEC.

Apellis focuses on developing therapies for diseases linked to the complement system, emphasizing innovation and patient care in various medical fields.

Apellis Pharmaceuticals announced the pricing of its underwritten public offering of 8,750,000 shares at $40.00 per share, totaling $350 million in gross proceeds. The offering aims to enhance the company's financial position and support further development in targeted C3 therapies. A 30-day option for underwriters to purchase an additional 1,312,500 shares is also available. The offering is set to close on November 18, 2021, pending customary conditions. J.P. Morgan, Goldman Sachs, and Evercore are leading the offering, emphasizing the company's focus on innovative therapeutics.

Apellis Pharmaceuticals (Nasdaq:APLS) has initiated a public offering of $300 million in common stock, all of which is being offered by the company. There is also an option for underwriters to purchase an additional 15% of the shares sold. The offering is subject to market conditions, and there are no guarantees regarding its completion. The shares are part of an automatically effective shelf registration statement filed with the SEC on January 7, 2020. Details will be provided in a preliminary prospectus supplement to be filed with the SEC.

Apellis Pharmaceuticals (Nasdaq: APLS) announced it received formal FDA feedback supporting its plans to submit a New Drug Application (NDA) for intravitreal pegcetacoplan aimed at treating geographic atrophy (GA) due to age-related macular degeneration. The NDA will utilize data from the Phase 3 DERBY and OAKS studies, alongside the Phase 2 FILLY study, all deemed adequate by the FDA. Apellis aims to submit the NDA in H1 2022 without needing additional trials. Over 1,500 patients participated in these studies, highlighting the company's commitment to addressing GA, a leading cause of blindness.